EGLN1 and peripheral arterial disease: Thus, in the context of ischemia, MØs with PHD2 haploinsufficiency may contribute to PAD treatment by diminishing PHD2 activity, which would in turn facilitate the stabilization of HIFs and lead to the acquisition of an M2-like phenotype.